Skip to main content

Table 1 Clinicopathological characteristics of all PTLD patients

From: Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation

Variable Distribution
Age at transplantation in years Median: 12.7 (0.4–65.4); mean: 22.3
Time to diagnosis after transplantation in years Median: 2.1 (0.3–19); mean: 3.8
Age at PTLD diagnosis in years Median: 15.7 (0.8–70.8); mean: 26.1
Age > 60 years at PTLD diagnosis n = 4 (11.1 %)
Age < 10 years at PTLD diagnosis n = 14 (38.9 %)
Age < 5 years at PTLD diagnosis n = 11 (30.6 %)
Late PTLD (>365 days after Tx) n = 24 (66.7 %)
Very early PLTD (<183 days after Tx) n = 4 (11.1 %)
Ciclosporine at PTLD diagnosis n = 15 (41.7 %)
Tacrolimus at PTLD diagnosis n = 16 (44.4 %)
CNI-free immunosuppression at PTLD diagnosis n = 5 (13.9 %)
Mycophenolat at PTLD diagnosis n = 19 (52.8 %)
Steroids at PTLD diagnosis n = 29 (80.6 %)
Steroid-free immunosuppression at PTLD diagnosis n = 7 (19.4 %)
mTOR inhibitors at PTLD diagnosis n = 1 (2.8 %)
Number of graft rejections prior to PTLD diagnosis Median: 0 (0–2); mean: 0.44
Number of graft rejections after PTLD diagnosis Median: 0 (0–1); mean: 0.25
Polymorphic PTLD n = 5 (13.9 %)
Monomorphic PTLD n = 28 (77.8 %)
Pure B cell neoplasm n = 29 (80.6 %)
Diffuse large B cell neoplasm n = 20 (55.6 %)
CD20 expression in tumor n = 32 (88.9 %)
EBV latent membrane protein or EBV-encoded RNA in tumor cells n = 26 (100.0 %a, 10 cases missing data)
Detection of monoclonal disease n = 9 (52.9 %a, 19 cases missing data)
Extranodal disease n = 24 (66.7 %)
Graft organ involvement n = 4 (11.1 %)
CNS involvement n = 7 (19.4 %)
Primary CNS lymphoma n = 4 (11.1 %)
Bone marrow involvement n = 6 (16.7 %)
Gastro-intestinal involvement n = 14 (38.9 %)
Lung involvement n = 3 (8.3 %)
Skin involvement n = 0 (0.0 %)
Number of sites involved Median: 2 (1–6); mean: 2.5
Stage IV disease n = 25 (69.4 %)
B-symptoms at PTLD diagnosis n = 4 (11.1 %)
Lactate dehydrogenase elevated at PTLD diagnosis n = 23 (71.9 %a, 4 cases missing data)
Hypoalbuminemia at PTLD diagnosis n = 17 (65.4 %a, 10 cases missing data)
EBV IgG at Tx n = 14 (45.2 %a, 5 cases missing data)
EBV IgM at Tx n = 1 (3.3 %a, 6 cases missing data)
EBV serology or DNA positive at PTLD diagnosis n = 31 (100.0 %a, 5 cases missing data)
EBV DNA at PTLD diagnosis n = 29 (96.7 %a, 6 cases missing data)
EBV IgG at PTLD diagnosis n = 21 (77.8 %a, 9 cases missing data)
CMV IgG at Tx n = 12 (35.3 %a, 2 cases missing data)
CMV IgM at Tx n = 3 (9.7 %a, 5 cases missing data)
CMV pp65 at Tx n = 1 (3.8 %a, 10 cases missing data)
CMV serology or DNA positive at PTLD diagnosis n = 23 (100 %a, 13 cases missing data)
CMV pp65 at PTLD diagnosis n = 1 (4.2 %a, 12 cases missing data)
CMV DNA at PTLD diagnosis n = 4 (22.2 %a, 18 cases missing data)
CMV IgM at PTLD diagnosis n = 7 (30.4 %a, 13 cases missing data)
CMV IgG at PTLD diagnosis n = 21 (77.8 %a, 9 cases missing data)
  1. Shown are the distributions of clinicopathological characteristics of 36 analyzed PTLD cases
  2. Tx transplantation, CNI-free calcineurin-inhibitor-free, EBV Epstein-Barr virus, CMV cytomegalovirus
  3. aOf evaluated cases